Clinical trial
Clinical Study Protocol No. VIA-2291-01, A Phase 2 Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging Study of the Effect of VIA-2291 on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event
NCT00358826 is registered in ClinicalTrials.gov with Tallikut Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical Study Protocol No. VIA-2291-01, A Phase 2 Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging Study of the Effect of VIA-2291 on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event
- Lead sponsor
- Tallikut Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2006
- Completion date
- September 30, 2008
- Enrollment
- 191 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.